Heidi Health
-65%
est. 2Y upside i
Heidi is the AI Care Partner designed to expand clinical capacity by automating administrative work – documentation, form filling, and task management - so clinicians can focus on patients. Used across emergency departments, general practice, and specialist clinics, Heidi supports more than 2 million consults each week in 110 languages from 116 countries.
Rank
#2059
Sector
AI Healthcare Technology
Est. Liquidity
~4Y
Data Quality
Data: HighHeidi Health operates in a large and rapidly growing AI healthcare market, demonstrating strong product adoption with over 2 million consultations supported weekly and positive outcomes from an NHS pilot.
Last updated: March 10, 2026
Heidi Health establishes itself as a clear market leader in the rapidly expanding AI medical scribe sector, leveraging its product-led growth and comprehensive 'AI Care Partner' platform to capture significant market share. Successful deep integrations with major EHR systems and continued international expansion drive revenue to $120M+ by 2028, justifying a $1.6B+ valuation (3.4x current) as a prime acquisition target or pre-IPO candidate.
Heidi Health maintains its strong growth trajectory and market position, successfully navigating competitive pressures from incumbents and other AI scribe vendors. Continued product innovation and customer adoption lead to revenue of $70M by 2028, resulting in an acquisition or IPO at a valuation of $815M (1.75x current), offering moderate returns for common shareholders.
Dominant incumbents like Microsoft and Epic aggressively expand their AI scribe offerings, leveraging existing EHR integrations and market power to commoditize the core AI scribe functionality. Heidi Health struggles to differentiate and faces significant pricing pressure, leading to slower growth and a down round or acquisition at a reduced valuation of $186M (-60% from current), significantly eroding common stock value due to liquidation preferences.
Preference Stack Risk
highFunding Intensity
21%Investors hold approximately $97M in liquidation preferences ahead of common stock. In an exit at or below the current $465M valuation, common stock holders would see their returns significantly reduced or eliminated until the $97M preference is covered.
Dilution Risk
moderateAs a Series B company, further funding rounds (Series C/D) are likely before an exit, which will lead to additional dilution for current equity holders.
Secondary Liquidity
limitedWhile platforms like Forge and EquityZen offer avenues for accredited investors to buy/sell private shares, current market activity for Heidi Health is low, meaning liquidity for employees is not guaranteed.
Questions to Ask at the Interview
Strategic questions based on Heidi Health's data — designed to show you've done your homework.
- 1
“Given the high incumbent threat from companies like Microsoft (with DAX/Dragon) and Epic, what is Heidi Health's long-term strategy to maintain its competitive moat and differentiate its 'AI Care Partner' platform beyond core scribe functionality?”
- 2
“With a reported $25M in revenue and a $465M valuation, how does Heidi Health plan to accelerate its revenue growth and market penetration to justify its current valuation and achieve a significant liquidity event within the next 3-5 years, especially considering the crowded market of over 100 AI scribe companies?”
- 3
“Considering the Series B funding in October 2025 and the $97M in total funding, what is the company's perspective on future funding rounds, potential dilution for common shareholders, and the anticipated timeline or mechanisms for employee liquidity (e.g., secondary markets, IPO, acquisition)?”
Community
Valuation Sentiment
Our model estimates -65% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.